PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Project

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Completed · 2012 until 2017

Müller Rüdiger, Forrer Silvia

Type

Clinical Studies

Range

Multicentric, KSSG as participating partner

Units

Rheumatologie

Status

Completed

Start Date

2012

End Date

2017

Financing

Industry

Study Design

Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment

Homepage

http://clinicaltrials.gov/ct2/show/NCT01212770

Brief description/objective

Official Title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion

Purpose:
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.